FDA Holds Mustang Bio's Gene Therapy IND For Compromised Immune System Disorder


The FDA has issued a hold, pending Chemistry, Manufacturing & Controls (CMC) clearance, on Mustang Bio Inc's MBIO Investigational New Drug (IND) application for MB-207 in patients with X-linked severe combined immunodeficiency (XSCID).

  • The application was submitted to initiate a pivotal Phase 2 study to assess MB-207 (lentiviral gene therapy) in patients who have been previously treated with a hematopoietic stem cell transplantation, and for whom re-treatment is indicated. 
  • The FDA has previously granted MB-207 Orphan Drug and Rare Pediatric Disease Designations. 
  • Related content: Benzinga's Full FDA Calendar.
  • An additional Phase 1/2 trial for XSCID in newly diagnosed infants is ongoing.
  • Mustang expects to initiate a pivotal Phase 2 trial of MB-107 in newly diagnosed infants with XSCID who are between two months to two years in Q3 of 2022. 
  • The primary efficacy endpoint will be event-free survival. 
  • XSCID, also known as bubble boy disease, is a rare genetic disorder characterized by the absence or lack of function of key immune cells, resulting in a severely compromised immune system.
  • Mustang was founded by Fortress Biotech Inc FBIO
  • Price Action: MBIO shares are closed at $1.30 on Monday.

Posted In: BiotechNewsPenny StocksHealth CareFDAGeneralBriefsgene therapyPhase 2 Trial